Asalam U Alikum @teammadkashmirA patient namely Hanifa begum W/o Gh Qadir sheikh R/o Shade Gundbala Tehsil Gundbala Distt Kupwara is suffering from blood cancer. His husband is a labour by profession and she needs ₹10 lac rupees.His family is not in condition to afford her treatment cost.Now its requested to general public to donate some amount in the account of victim.The case is highly verified by Team MAD.For more verification please call on 919103263881Account no: 059404021000277ifsc code: JAKA0QLMCHKAccount holder name:Hanifa Begunphone no: 919103263881 If you cannot donate please share so that others can donate. Remember your small donations can save precious life_____________________________________________________Video : muafiqCase highly Verified by 1.Team M. A. D KASHMIR ( The voice of needy people) (a charitable group by kash graph global ) 2 @baabarr_mudacer@kashgraph@umar bashir#share #post #and #save #precious #life.
A three-time leukemia survivor got quite the surprise on Thursday in Phoenix when he met 13 people who helped save his life with blood donations.
GRAIL, a Silicon Valley startup, created the Galleri test, which can screen for more than 50 cancers by looking at blood for DNA shed by cancer tumors. If it sees that DNA, then it predicts where the cancer is. A positive result isn’t always accurate, but researchers at the National Cancer Institute say study results so far could potentially revolutionize cancer screening, and they’re designing bigger studies. » Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC» Watch more NBC video: http://bit.ly/MoreNBCNewsNBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.Connect with NBC News Online!NBC News App: https://smart.link/5d0cd9df61b80Breaking News Alerts: https://link.nbcnews.com/join/5cj/breaking-news-signup?cid=sm_npd_nn_yt_bn-clip_190621Visit NBCNews.Com: http://nbcnews.to/ReadNBCFind NBC News on Facebook: http://nbcnews.to/LikeNBCFollow NBC News on Twitter: http://nbcnews.to/FollowNBC#Cancer #Medicine #HealthNewsNew Blood Test Could Change The Way Cancer Is Detected
Another master of the bass has left us. Leonard Hubbard, aka Hub, has died from a form of blood cancer called multiple myeloma. He was 62 years old. The Roots made the announcement on their social media.
CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, discusses 2-year results from the CARTITUDE-1 study evaluating cilta-cel in heavily pre-treated, relapsed/refractory multiple myeloma patients.Multiple myeloma is a blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Myeloma cells also produce inactive clones of abnormal antibodies that may negatively affect the bones and kidneys. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation. While the disease is treatable, relapses are common and some patients are refractory to first line treatment.As Dr. Martin explains, the CARTITUDE-1 study is an ongoing Phase 1b/2, open-label, multi-center study evaluating the safety and efficacy of cilta-cel in adults with relapsed and/or refractory multiple myeloma. Patients received a single cilta-cel infusion (target dose 0.75×106 CAR+ viable T cells/kg) 5–7 days after lymphodepletion. Primary objectives of the study were to characterize cilta-cel safety confirm the recommended dose, and to evaluate efficacy.Previous data was presented at the American Society of Hematology Meeting & Exposition in 2020 (ASH 2020) when the median length of follow-up was 12 months. More recently, additional follow-up data was presented at ASH 2021, when the median length of follow-up was 18 months. This 2-year follow-up data demonstrated that in the 97 patients reported on, the overall response rate was 98% and the stringent complete response was 83% (compared to 67% at 12-month follow-up). The median progression-free survival was not estimable but, according to Dr. Martin, was approximately 61%.Cilta-cel, as a treatment from relapsed and/or refractory multiple myeloma patients, is currently under review by the FDA. They are set to make a decision by February 28, 2022.
Leonard Hubbard dead: The Roots bassist dies aged 62 ‘from blood cancer’Please subscribe: https://www.youtube.com/channel/UCMZ4c7pmlGw3VVFu0KOuZPg?sub_confirmation=1————————————–Source: https://www.express.co.uk/celebrity-news/1537480/URL-Leonard-Hubbard-dead-cause-of-death-dies-The-Roots-Bassist-cancer-battle-news-latest
Interview with Nathan Sweeny of the HealthTree Foundation at ASH 2021. Filmed December 13, 2021.The Myeloma Crowd brings information from the experts to the patients! Learn more at https://www.myelomacrowd.org/HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of a study investigating optimal treatment sequencing in multiple myeloma. With the available options for treatment expanding rapidly, determining the best strategies for upfront treatment and subsequent lines of therapy is of critical importance. In this analysis, the clinical value of daratumumab (DARA) first line compared to later lines was examined in patients with newly diagnosed transplant-ineligible multiple myeloma, since it is unclear where it performs optimally. It was shown that using DARA, lenalidomide, and dexamethasone (D-Rd) first line substantially improved overall survival compared with delaying DARA-based treatment until second line. Due to higher attrition rates in second line and beyond, the results demonstrate that achieving the longest possible progression-free survival in first line is key to optimize overall survival outcomes and therefore, saving DARA to later lines is a suboptimal approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
To learn more about Fenbendazole for Multiple Myeloma please click here: https://peoplebeatingcancer.org/multiple-myeloma-therapy-fenbendazole-aka-the-vet-cure-vet-medicine/
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, discusses the updated, long-term data from the phase 2 CAPTIVATE study. This study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic leukemia (CLL); data from this trial was recently presented at the American Society of Hematology Meeting & Exposition (ASH 2021). CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. The disease is treatable, but relapse is very common.As Dr. Ghia explains, the CAPTIVATE study is a multicenter, double-blind, phase 2 study with previously untreated CLL patients under the age of 70 years. Patients were given 3 cycles of ibrutinib and an additional 12 cycles of ibrutinib plus venetoclax. Patients who had confirmed rates of undetectable minimal residual disease (uMRD) were then randomized to receive ibrutinib or placebo. Patients who did not meet the definition of undetectable MRD were randomized to receive ibrutinib alone or continued combination therapy. The endpoints presented on at ASH 2021 included: 2-year disease-free survival rate (defined as survival without progression or MRD relapse post-randomization) in patients with confirmed uMRD randomized to placebo vs ibrutinib, rates of uMRD (by 8-color flow cytometry), investigator-assessed best response per iwCLL, investigator-assessed PFS, and adverse events (AEs).Dr. Ghia goes on to discuss the long-term data. No new MRD relapses, progressions, or deaths in patients with confirmed uMRD occured since data from the CAPTIVATE trial were presented last year. The 2-year disease free survival (DFS) rate in the MRD-guided placebo arm remained high at 95% while 3-year progressive free survival (PFS) rates were greater than 95% across all randomized treatment arms. The results in patients with confirmed uMRD support the potential for treatment-free remission with fixed-duration treatment, including in patients with high-risk features. High rates of uMRD were achieved; the safety profile of ibrutinib plus venetoclax was consistent with the known safety profiles of each agent. The most frequent grade 3/4 AEs were neutropenia, hypertension, thrombocytopenia, and diarrhea.